Author

Michael J. Gerber

Observed names: MICHAEL J. GERBER, Michael Gerber, Michael J Gerber

Institutions: The Lundquist Institute, Baylor College of Medicine, Justus-Liebig-Universität Gießen, Medical University of Graz, Gilead Sciences (United States), The University of Texas Southwestern Medical Center, University of Bologna

Observed institutions: Cleveland Clinic, University of Arizona, The Lundquist Institute, Baylor College of Medicine, Justus-Liebig-Universität Gießen, Medical University of Graz, RTOG Foundation, Gilead Sciences (United States), Wake Forest University Health Sciences, Wake Forest University, The University of Texas Southwestern Medical Center, University of Bologna

OpenAlex ID: A5109173451

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

2008 · Nazzareno Galiè, Horst Olschewski, et al. · Circulation · 1,083

Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities

2008 · Michael D. McGoon, Adaani E. Frost, et al. · CHEST Journal · 187

Efficacy and Safety of Darusentan in Patients With Resistant Hypertension: Results From a Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Study

2007 · Henry R. Black, George L. Bakris, et al. · Journal of Clinical Hypertension · 106

RSR13 Plus Cranial Radiation Therapy in Patients With Brain Metastases: Comparison With the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database

2003 · Edward Shaw, Charles Scott, et al. · Journal of Clinical Oncology · 99

A Phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics

2001 · Brian D Kavanagh, Shiv R Khandelwal, et al. · International Journal of Radiation Oncology*Biology*Physics · 38

Allosteric Modification of Oxygen Delivery by Hemoglobin

2001 · Joyce A. Wahr, Michael Gerber, et al. · Anesthesia & Analgesia · 36

Rationale and Design of the Enoximone Clinical Trials Program

2005 · Brian D. Lowes, Simon F. Shakar, et al. · Journal of Cardiac Failure · 30

Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: Results of the oral enoximone in intravenous inotrope-dependent subjects trial

2007 · Arthur M. Feldman, Ron M. Oren, et al. · American Heart Journal · 29

Ambrisentan Has No Clinically Relevant Effect on the Pharmacokinetics or Pharmacodynamics of Warfarin

2006 · Michael J. Gerber, Christopher Dufton, et al. · CHEST Journal · 20

No Clinically Relevant Pharmacokinetic Interaction Between Ambrisentan and Sildenafil

2006 · Christopher Dufton, Michael J. Gerber, et al. · CHEST Journal · 19

Ambrisentan for Pulmonary Arterial Hypertension

2005 · Lewis J Rubin, Christopher Dufton, et al. · Future Cardiology · 19

The Rationale for, and Effects of Oxygen Delivery Enhancement to Ischemic Brain in a Feline Model of Human Strokea

1997 · EGON M. R. DOPPENBERG, JOSEPH C. WATSON, et al. · Annals of the New York Academy of Sciences · 12

Allosteric Modification of Hemoglobin by RSR13 as a Therapeutic Strategy

2003 · Robert P. Steffen, Jean-Francois Liard, et al. · Advances in experimental medicine and biology · 5

2179 A phase Ib study to evaluate repeated daily intravenous doses of RSR 13 administered to cancer patients receiving concurrent radiation therapy

1997 · Brian D. Kavanagh, Shiv R. Khandelwal, et al. · International Journal of Radiation Oncology*Biology*Physics · 2

Works count: 15

Citation count: 1,685

H-index: 12

I10-index: 12